AI Robotics in Medicine

Federal action meets market momentum and public skepticism: HHS’s sweeping request for input probes how regulation, reimbursement, and R&D can speed clinical AI, while health systems report ambient scribes reducing documentation burden and burnout. Yet Americans’ openness to AI in care has dropped to 42% from 52% in 2024, even as investment and deployments expand—$4B to digital health startups in Q1 2026, UnitedHealth scaling AI, Lilly’s Insilico deal up to $2.75B—and vendors launch new platforms and pilots. Watch how HHS guidance and reimbursement signals set evidence bars and risk controls, and whether public‑facing efforts like Munich’s “2036 – Healthy with AI?” plus demonstrable clinical gains can close the trust gap.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

Geography: United States, Boston, San Francisco Bay Area, Seattle, United Kingdom, London, Cambridge (UK), European Union, Berlin, Munich, Paris, Zurich, Canada, Toronto, Montreal, Israel, Tel Aviv, China, Beijing, Shanghai, Shenzhen, Japan, Tokyo, South Korea, Seoul, Singapore, India, Bengaluru, Hyderabad, United Arab Emirates, Abu Dhabi, Dubai, Australia, Sydney, Melbourne

1. HHS Seeks Input on Clinical AI as Deployment Grows, Public Trust Slips

U.S. healthcare AI is entering a consolidation phase: Washington wants input, buyers want proof, and the public wants reassurance.

HHS issued a sweeping Request for Information on how regulation, reimbursement, and R&D could accelerate clinical AI adoption, even as major U.S. health systems report that ambient AI scribes are already reducing documentation burden and burnout, according to the American Hospital Association.

Yet a new Ohio State Wexner Medical Center survey shows Americans’ openness to AI in their care has fallen to 42% from 52% in 2024.

Investment and deployments continue: digital health startups raised $4B in Q1 2026; UnitedHealth Group is scaling AI across core operations; and Eli Lilly struck an Insilico Medicine deal worth up to $2. 75B.

Vendor activity is brisk, with Bluesight launching the Prism platform, Matricis. ai piloting EndomAI with SimonMed, and Arcadia expanding leadership for AI-driven performance.

Abroad, Munich’s M1 alliance is creating “2036 – Healthy with AI? ” to co-develop a public-facing digital patient journey.

Key facts:

- HHS issued a sweeping RFI to accelerate clinical AI via regulation, reimbursement, and R&D.

- AHA cites real-world evidence that ambient AI scribes cut documentation burden and burnout.

- Openness to AI in care fell to 42%, from 52% in 2024.

- Digital health startups raised $4B in Q1 2026, up $1B year over year.

- UnitedHealth Group is deploying AI across claims, fraud detection, documentation, and billing.

Why it matters: A federal RFI, payer deployment, and a major pharma deal signal AI’s shift from pilots to core strategy. If policymakers pair incentives with guardrails, hospitals may act on real‑world evidence such as ambient scribes’ burnout reductions. But declining public openness and trust could slow uptake unless developers and health systems communicate transparently and involve patients—mirrored by Munich’s public‑engagement project. New platforms and pilots must prove clinical value and workflow fit; their outcomes, along with responses to the HHS RFI, will steer capital allocation and set adoption velocity.

CrescendoTumAithority